Gene-Editing shot could slash cholesterol for good
NCT ID NCT06164730
First seen Jun 24, 2026 · Last updated Aug 04, 2026 · Updated 7 times
Summary
This early-stage trial tests a single IV dose of VERVE-102, a gene-editing drug designed to permanently lower LDL (bad) cholesterol by turning off a specific gene in the liver. It involves 85 adults with inherited high cholesterol or early heart disease who still need lower cholesterol despite current treatments. The main goal is to check safety, but researchers will also measure how much cholesterol drops.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VERVE-102 (a gene-editing drug given by IV infusion)
- What this could lead to
- If successful, this could lead to a one-time treatment that dramatically lowers bad cholesterol, reducing heart attack risk without daily pills.
- What could go wrong
- This is an early, small safety trial (Phase 1b) with only 85 people. It may not work as hoped, and there are unknown risks from gene editing, including possible liver effects or immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Study Center
RECRUITINGDothan, Alabama, 36305, United States
-
Clinical Study Center
RECRUITINGPomona, California, 91768, United States
-
Clinical Study Center
RECRUITINGBoca Raton, Florida, 33434, United States
-
Clinical Study Center
RECRUITINGJacksonville, Florida, 32216, United States
-
Clinical Study Center
RECRUITINGWinter Park, Florida, 32789, United States
-
Clinical Study Center
RECRUITINGIndianapolis, Indiana, 46237, United States
-
Clinical Study Center
RECRUITINGHigh Point, North Carolina, 27260, United States
-
Clinical Study Center
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Clinical Study Center
RECRUITINGDeSoto, Texas, 75115, United States
-
Clinical Study Center
RECRUITINGRenton, Washington, 98057, United States
-
Clinical Study Center
RECRUITINGAdelaide, Australia
-
Clinical Study Center
RECRUITINGMelbourne, Australia
-
Clinical Study Center
RECRUITINGSydney, Australia
-
Clinical Study Center
RECRUITINGChicoutimi, Canada
-
Clinical Study Center
RECRUITINGHamilton, Canada
-
Clinical Study Center
RECRUITINGMontreal, Canada
-
Clinical Study Center
RECRUITINGQuébec, Canada
-
Clinical Study Center
RECRUITINGToronto, Canada
-
Clinical Study Center
RECRUITINGVancouver, Canada
-
Clinical Study Center
RECRUITINGRehovot, Israel
-
Clinical Study Center
RECRUITINGChristchurch, New Zealand
-
Clinical Study Center
RECRUITINGBirmingham, United Kingdom
-
Clinical Study Center
RECRUITINGCambridge, United Kingdom
-
Clinical Study Center
RECRUITINGEdinburgh, United Kingdom
-
Clinical Study Center
RECRUITINGLondon, United Kingdom
-
Clinical Study Center
RECRUITINGManchester, United Kingdom
-
Clinical Study Center
RECRUITINGNottingham, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a daily pill help kids with inherited high cholesterol?
- Gene-Editing heart therapy under 15-Year watch
- Gene-Editing shot takes aim at inherited high cholesterol
- Real-World study tracks cholesterol drug inclisiran in heart patients
- New pill could tame inherited high cholesterol
- AI app aims to keep young hearts healthy after hospital discharge